company background image
BIOT logo

Biotage OM:BIOT 株式レポート

最終価格

SEK 185.50

時価総額

SEK 14.8b

7D

2.8%

1Y

72.7%

更新

27 Sep, 2024

データ

会社財務 +

Biotage AB (publ)

OM:BIOT 株式レポート

時価総額:SEK 14.8b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

BIOT 株式概要

バイオテージAB(publish)は、創薬・医薬品開発、分析試験、水質・環境試験の分野でソリューションと製品を提供している。

BIOT ファンダメンタル分析
スノーフレーク・スコア
評価3/6
将来の成長4/6
過去の実績4/6
財務の健全性6/6
配当金3/6

Biotage AB (publ) 競合他社

価格と性能

の歴代最高値、変動、値下がりまとめBiotage
過去の株価
現在の株価SEK 185.50
52週高値SEK 202.20
52週安値SEK 83.05
ベータ0.85
11ヶ月の変化-3.39%
3ヶ月変化13.73%
1年変化72.72%
33年間の変化-21.73%
5年間の変化82.22%
IPOからの変化81.86%

最新ニュース

Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings

Sep 17
Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings

Recent updates

Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings

Sep 17
Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings

Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Jul 19
Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?

Jun 08
Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?

Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?

May 21
Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?

Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Apr 28
Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Biotage's (STO:BIOT) Dividend Will Be SEK1.60

Apr 17
Biotage's (STO:BIOT) Dividend Will Be SEK1.60

Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next

Apr 08
Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Apr 03
Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Mar 04
Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Feb 22
Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%

Feb 21
Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%

Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next

Feb 18
Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next

Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet

Feb 08
Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet

Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)

Jan 07
Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)

At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?

Dec 08
At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?

Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)

Oct 27
Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)

Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

Jul 12
Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued

Jun 08
An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued

Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth

May 24
Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth

Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Apr 05
Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely

Mar 12
These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely

Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?

Feb 21
Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?

Are Biotage AB (publ) (STO:BIOT) Investors Paying Above The Intrinsic Value?

Jan 06
Are Biotage AB (publ) (STO:BIOT) Investors Paying Above The Intrinsic Value?

Biotage (STO:BIOT) Seems To Use Debt Rather Sparingly

Dec 03
Biotage (STO:BIOT) Seems To Use Debt Rather Sparingly

Is Now The Time To Look At Buying Biotage AB (publ) (STO:BIOT)?

Oct 27
Is Now The Time To Look At Buying Biotage AB (publ) (STO:BIOT)?

Estimating The Fair Value Of Biotage AB (publ) (STO:BIOT)

Oct 07
Estimating The Fair Value Of Biotage AB (publ) (STO:BIOT)

Biotage (STO:BIOT) Could Easily Take On More Debt

Sep 03
Biotage (STO:BIOT) Could Easily Take On More Debt

Is There Now An Opportunity In Biotage AB (publ) (STO:BIOT)?

Jul 10
Is There Now An Opportunity In Biotage AB (publ) (STO:BIOT)?

A Look At The Fair Value Of Biotage AB (publ) (STO:BIOT)

Jun 25
A Look At The Fair Value Of Biotage AB (publ) (STO:BIOT)

Do Biotage's (STO:BIOT) Earnings Warrant Your Attention?

May 28
Do Biotage's (STO:BIOT) Earnings Warrant Your Attention?

Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Apr 23
Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Biotage (STO:BIOT) Is Paying Out A Larger Dividend Than Last Year

Mar 29
Biotage (STO:BIOT) Is Paying Out A Larger Dividend Than Last Year

Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

Mar 14
Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

株主還元

BIOTSE Life SciencesSE 市場
7D2.8%2.5%1.9%
1Y72.7%80.5%24.3%

業界別リターン: BIOT過去 1 年間で79.8 % の収益を上げたSwedish Life Sciences業界を下回りました。

リターン対市場: BIOT過去 1 年間で19.8 % の収益を上げたSwedish市場を上回りました。

価格変動

Is BIOT's price volatile compared to industry and market?
BIOT volatility
BIOT Average Weekly Movement4.6%
Life Sciences Industry Average Movement8.5%
Market Average Movement5.6%
10% most volatile stocks in SE Market11.7%
10% least volatile stocks in SE Market3.2%

安定した株価: BIOT過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: BIOTの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。

会社概要

設立従業員CEO(最高経営責任者ウェブサイト
1969667Frederic Vanderhaegenwww.biotage.com

Biotage AB (publish)は、創薬・医薬品開発、分析試験、水質・環境試験の分野でソリューションと製品を提供している。有機およびペプチド合成ソリューション、フラッシュクロモセラピー、蒸発およびワークアップ製品、フラッシュシステム、サンプル前処理製品、プラスミド精製ソリューション、オリゴ合成ソリューション、金属スカベンジャーおよび試薬、ならびにアクセサリーとスペアパーツを提供。また、臨床・バイオ分析、法医学・毒物学、ドーピングコントロール動物・ヒト、環境、食品・農業分野のサンプル調製ソリューション、消耗品・システム、抗体・タグタンパク精製を含むタンパク質精製ソリューション、自動化システム、カスタムパッキングサービス、イオン交換、逆相、順相、ゲルろ過PhyTipカラムなども提供している。同社は、製薬会社、バイオテクノロジー企業、受託研究・製造機関、診断、臨床、環境保護、食品安全、臨床、法医学、学術研究機関向けに製品を販売している。米州、欧州、中東、アフリカ、アジア太平洋を含む80カ国以上で事業を展開。バイオテージAB(publ)は1969年に設立され、スウェーデンのウプサラに本社を置く。

Biotage AB (publ) 基礎のまとめ

Biotage の収益と売上を時価総額と比較するとどうか。
BIOT 基礎統計学
時価総額SEK 14.85b
収益(TTM)SEK 251.00m
売上高(TTM)SEK 2.08b

59.2x

PER(株価収益率

7.1x

P/Sレシオ

収益と収入

最新の決算報告書(TTM)に基づく主な収益性統計
BIOT 損益計算書(TTM)
収益SEK 2.08b
売上原価SEK 774.00m
売上総利益SEK 1.30b
その他の費用SEK 1.05b
収益SEK 251.00m

直近の収益報告

Jun 30, 2024

次回決算日

Oct 23, 2024

一株当たり利益(EPS)3.14
グロス・マージン62.73%
純利益率12.08%
有利子負債/自己資本比率4.0%

BIOT の長期的なパフォーマンスは?

過去の実績と比較を見る

配当金

0.9%

現在の配当利回り

51%

配当性向